Anti-senescence compounds and uses for the treatment of cancer

A compound selected from

• i) a peptide comprising an amino acid sequence that is at least 70% identical to the amino acid sequence
• (SEQ ID NO:
• 1)
• X3X2X4X5X7X5X4X4X6X18X8X3QNX9X8X10X10X11X12S*X13X14X11X11,
• wherein
• S* can be S or is absent;
• X2 is absent or is selected from K, E, R, and H;
• X3 is absent or selected from A, J, and S;
• X4 is selected from I, Z, and L, wherein Z is Cyclo-Hexyl-Alanine;
• X5 is selected from A, G, S, E, and D;
• X6 is selected from E and D;
• X7 is selected from J, G, Q, A, S, and P;
• X8 is selected from B, W, Y, and F, wherein B is 2-Methyl-Tryptophan;
• X9 is absent or is selected from A and G;
• X10 is absent or is selected from A and N;
• X11 is selected from R and K;
• X12 is absent or is R;
• X13 is absent or is selected from G and S;
• X14 is absent or is selected from A and C;
• and
• X18 is selected from A and E;
• wherein J is Fmoc-L-2-(4′-pentenyl)alanine;
• with the provisio that either none or two Js are present that form a staple;
• ii) the peptide according to i) comprising at least 80% D-amino acids, and
• iii) a retro inverso peptide according to i) or ii),
• and pharmaceutically acceptable salts thereof;
• and
• wherein said compound induces apoptosis in senescent, scarred cells, and/or cancerous cells.